Advertisement

Clinical Drug Investigation

, Volume 25, Issue 3, pp 175–182 | Cite as

Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients

A Randomised, Double-Blind, Multicentre Study
Original Research Article

Abstract

Background: Angiotensin-converting enzyme inhibitors have been proposed as first-choice drugs for antihypertensive therapy in elderly subjects because of their demonstrated efficacy and safety. However, no information is currently available on the use of zofenopril in elderly hypertensive patients.

Objective: To assess the efficacy and safety of zofenopril (30 or 60mg once daily) compared with lisinopril (10 or 20mg once daily).

Patients and methods: Patients aged ≥65 years with mild to moderate essential hypertension (sitting diastolic blood pressure [DBP] ≥90mm Hg and ≤110mm Hg) were included in the study. They were randomised to receive either zofenopril 30mg or lisinopril 10mg. Blood pressure and heart rate were measured at baseline and after 4 and 12 weeks of treatment. Patients underwent electrocardiography and evaluation of laboratory parameters at baseline and after 12 weeks. Ambulatory blood pressure monitoring (ABPM) was also performed at baseline and after 12 weeks. After 4 weeks drug doses were doubled in patients whose sitting DBP was ≥90mm Hg. The primary endpoint was to achieve sitting DBP values <90mm Hg or a reduction of sitting DBP >10mm Hg after 12 weeks of treatment.

Results: 181 patients were randomised to treatment and 164 patients completed the study. Thirty-three patients were included in the analysis of 24-hour blood pressure monitoring. The percentage of patients with normalised sitting DBP (<90mm Hg) and the rate of treatment responders (reduction of sitting DBP ≥10mm Hg) were not significantly different between the two treatment groups (normalised: zofenopril 81.3% vs lisinopril 76.7%; responders: zofenopril 74.7% vs lisinopril 77.8%). At the end of the treatment sitting DBP was not significantly different between the two treatment groups (zofenopril 82.2 ± 6.6mm Hg vs lisinopril 82.0 ± 7.8mm Hg). Eight percent of patients experienced adverse events in the zofenopril group and 9% in the lisinopril group. A small percentage of adverse events (4%) was related to treatment and reported in the zofenopril group.

Conclusions: In elderly hypertensive patients, treatment with zofenopril was effective and well tolerated. Efficacy and safety were comparable with those of lisinopril.

Keywords

Lisinopril Ambulatory Blood Pressure Ambulatory Blood Pressure Monitoring Office Blood Pressure Moderate Essential Hypertension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This study was supported by a grant from Menarini Industrie Farmaceutiche Riunite. E. Malacco was a paid consultant for Menarini Industrie Farmaceutiche Riunite at the time of the study.

References

  1. 1.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265(24): 3255–64CrossRefGoogle Scholar
  2. 2.
    MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12CrossRefGoogle Scholar
  3. 3.
    Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338(8778): 1281–5PubMedCrossRefGoogle Scholar
  4. 4.
    Staessen LA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet 1997; 350(9080): 757–64PubMedCrossRefGoogle Scholar
  5. 5.
    Leonetti G, Zanchetti A. Results of antihypertensive treatment trials in the elderly. Am J Geriatr Cardiol 2002; 11(1): 41–7PubMedCrossRefGoogle Scholar
  6. 6.
    World Health Organization-International Society of Hypertension (WHO-ISH) Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17(2): 151–83Google Scholar
  7. 7.
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19): 2560–72PubMedCrossRefGoogle Scholar
  8. 8.
    Schnaper HW. Angiotensin converting enzyme inhibitors for systemic hypertension in young and elderly patients. Am J Cardiol 1992; 69(10): 54C–8CPubMedCrossRefGoogle Scholar
  9. 9.
    Leonetti G, Cuspidi C. Choosing the right ACE inhibitor: a guide to selection. Drugs 1995; 49(4): 516–35PubMedCrossRefGoogle Scholar
  10. 10.
    Israili ZH, Hall WD. ACE inhibitors. Differential use in elderly patients with hypertension. Drugs Aging 1995; 7(5): 355–71PubMedCrossRefGoogle Scholar
  11. 11.
    Borghi C, Ambrosioni E. Survival of myocardial infarction long-term evaluation-2 working party: double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003; 145(1): 80–7PubMedCrossRefGoogle Scholar
  12. 12.
    Langtry HD, Markham A. Lisinopril: a review of its pharmacology and clinical efficacy in elderly patients. Drugs Aging 1997; 10(2): 131–66PubMedCrossRefGoogle Scholar
  13. 13.
    Laher MS, Natin D, Rao SK, et al. Lisinopril in elderly patients with hypertension. J Cardiovasc Pharmacol 1987; 9 Suppl. 3: S69–71PubMedCrossRefGoogle Scholar
  14. 14.
    Pool Pool JL, Nelson EB, Taylor AA. Clinical experience and rationale for angiotensin-converting enzyme inhibition with lisinopril as the initial treatment for hypertension in older patients. Am J Med 1988; 85(3B): 19–24CrossRefGoogle Scholar
  15. 15.
    Chan P, Lin CN, Tomlinson B, et al. Additive effects of diltiazem and lisinopril in the treatment of elderly patients with mild-to-moderate hypertension. Am J Hypertens 1997; 10 (7 Pt 1): 743–9PubMedCrossRefGoogle Scholar
  16. 16.
    Lacourciere Y, Gagne C. Influence of zofenopril and low doses of hydrochlorothiazide on plasma lipoproteins in patients with mild to moderate essential hypertension. Am J Hypertens 1989; 2 (11 Pt 1): 861–4PubMedGoogle Scholar
  17. 17.
    Elijovich F, Laffer CL, Schiffrin EL. The effects of atenolol and zofenopril on plasma atrial natriuretic peptide are due to their interactions with target organ damage of essential hypertensive patients. J Hum Hypertens 1997; 11(5): 313–9PubMedCrossRefGoogle Scholar
  18. 18.
    Borghi C, Bacchelli S, Degli Esposti D, et al. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opin Pharmacother 2004; 5(9): 1965–77PubMedCrossRefGoogle Scholar
  19. 19.
    Mancia G, Parati G. The role of ambulatory blood pressure monitoring in elderly hypertensive patients. Blood Press Suppl 2000; 2: 12–6PubMedCrossRefGoogle Scholar
  20. 20.
    Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107(10): 1401–6PubMedCrossRefGoogle Scholar
  21. 21.
    Kantola I, Terent A, Kataja M, et al. ACE inhibitor therapy with spirapril increases nocturnal hypotensive episodes in elderly hypertensive patients. J Hum Hypertens 2001; 15(12): 873–8PubMedCrossRefGoogle Scholar
  22. 22.
    Lacourciere Y, Provencher P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. Br J Clin Pharmacol 1989; 27(3): 371–6PubMedCrossRefGoogle Scholar
  23. 23.
    Whelton A, Dunne Jr B, Glazer N, et al. Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension. J Hum Hypertens 1992; 6(4): 325–31PubMedGoogle Scholar
  24. 24.
    Tomei R, Rossi L, Carbonieri E, et al. Antihypertensive effect of lisinopril assessed by 24-hour ambulatory monitoring: a double-blind, placebo-controlled, cross-over study. J Cardiovasc Pharmacol 1992; 19(6): 911–4PubMedCrossRefGoogle Scholar
  25. 25.
    Taddei S, Omboni S, Ghiadoni L, et al. Combination of lisinopril and nifedipine GITS increases blood pressure control compared with single drugs in essential hypertensive patients. J Cardiovasc Pharmacol 2003; 41(4): 579–85PubMedCrossRefGoogle Scholar
  26. 26.
    Gourlay S, McNeil J, Forbes A, et al. Differences in the acute and chronic antihypertensive effects of lisinopril and enalapril assessed by ambulatory blood pressure monitoring. Clin Exp Hypertens 1993; 15(1): 71–89PubMedCrossRefGoogle Scholar
  27. 27.
    Conway J, Coats A. Value of ambulatory blood pressure monitoring in clinical pharmacology. J Hypertens Suppl 1989; 7(3): S29–32PubMedGoogle Scholar
  28. 28.
    European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21(6): 1011–53CrossRefGoogle Scholar
  29. 29.
    Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25(3): 305–13PubMedCrossRefGoogle Scholar
  30. 30.
    Fagard RH. Epidemiology of hypertension in the elderly. Am J Geriatr Cardiol 2002; 11(1): 23–8PubMedCrossRefGoogle Scholar
  31. 31.
    Franklin SS, Jacobs MJ, Wong ND, et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001; 37(3): 869–74PubMedCrossRefGoogle Scholar
  32. 32.
    Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 2000; 14(2): 83–90PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Medicina Interna IIIOspedale ‘L. Sacco’MilanoItaly

Personalised recommendations